A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction

IgA nephropathy frequently leads to progressive CKD. Although interest surrounds use of immunosuppressive agents added to standard therapy, several recent studies have questioned efficacy of these agents. Depleting antibody-producing B cells potentially offers a new therapy. In this open label, mult...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American Society of Nephrology 2017-04, Vol.28 (4), p.1306-1313
Hauptverfasser:	Lafayette, Richard A, Canetta, Pietro A, Rovin, Brad H, Appel, Gerald B, Novak, Jan, Nath, Karl A, Sethi, Sanjeev, Tumlin, James A, Mehta, Kshama, Hogan, Marie, Erickson, Stephen, Julian, Bruce A, Leung, Nelson, Enders, Felicity T, Brown, Rhubell, Knoppova, Barbora, Hall, Stacy, Fervenza, Fernando C
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Clinical Research Female Glomerulonephritis, IGA - complications Glomerulonephritis, IGA - drug therapy Glomerulonephritis, IGA - immunology Glomerulonephritis, IGA - physiopathology Humans Immunologic Factors - therapeutic use Kidney - physiopathology Male Middle Aged Proteinuria - etiology Rituximab - therapeutic use Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	IgA nephropathy frequently leads to progressive CKD. Although interest surrounds use of immunosuppressive agents added to standard therapy, several recent studies have questioned efficacy of these agents. Depleting antibody-producing B cells potentially offers a new therapy. In this open label, multicenter study conducted over 1-year follow-up, we randomized 34 adult patients with biopsy-proven IgA nephropathy and proteinuria >1 g/d, maintained on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with well controlled BP and eGFR
ISSN:	1046-6673 1533-3450
DOI:	10.1681/ASN.2016060640